Longevity Biotechnology Association Launch
The LBA launched on November 17, 2021 in London! Learn more about our organization or become a member.
"Age is just a number – and that number is $33trn" - Via AGBI
As companies join the global race to prolong life, the Gulf is positioned to lead the way in preventative medicine.
Should Aging Be Called A Disease?
The LBA presents members Drs. Nir Barzilai and David Sinclair discussing whether aging should be classified as a disease and the associated pros and cons.
Longevity dividends: How to frame the concept and engage with people of influence
Longevity Biotechnology Association features Jim Mellon and Andrew Scott for our October Roundtable.
LBA Racing to a Longevity Trial
Celine Halioua CEO of Loyal/Cellular Longevity talks to James Peyer CEO of Cambrian Bio about Loyal's approach to longevity clinical trials.
LBA January 2023 Roundtable: Insights into the Gerotherapeutics Roadmap with Michael Ringel
Nir Barzilai and Michael Ringel of Boston Consulting Group discuss how to move the geroscience field forward.
No more ‘playing God’: How the longevity field is trying to recast its work as serious science (via Stat+)
Targeting aging to prevent diseases – interview with Dr. Nir Barzilai
An interview Dr. Nir Barzilai, a renowned geroscientist and quadraScope's scientific advisor. Among various topics, we covered the mission of two new longevity-focused organizations: the Longevity Biotechnology Association and the Healthy Longevity Medicine Society. We also discussed the impact of the Targeting Aging with Metformin (TAME) trial and key discoveries made by the SuperAgers initiative.